Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers
Open Access
- 19 May 2011
- journal article
- clinical trial
- Published by BMJ in Archives of Disease in Childhood
- Vol. 96 (8), 744-751
- https://doi.org/10.1136/adc.2009.180596
Abstract
Background A New Zealand serogroup B meningococcal epidemic prompted trials of a strain-specific (B:4:P1.7-2,4) outer membrane vesicle vaccine (MeNZB). Methods Adults, school children, and infants provided serum after three MeNZB doses to evaluate antibody persistence via serum bactericidal assay. Toddler (16–24 months) non-responders and responders received a fourth MeNZB dose 11 and 17 months after dose three respectively. Response was a ≥4-fold rise in bactericidal titre to a titre of ≥8. Results Geometric mean bactericidal titres (GMTs), with 95% CI, after dose 3: adults: 27 (14–52), 5 (3–11), and 7 (3–15) at 1, 10, and 22 months; school children: 18 (13–25) and 4 (3–6) at 1 and 4 months; infants: 27 (19–39) and 2 (2–3) at 1 and 7 months. The titre achieved after priming significantly influenced persistence. Toddler non-responder GMTs were 4 (3–5) and 1 (1–1) at 1 and 11 months after dose 3 and 69 (46–106) 1 month after dose 4. Responder GMTs were 24 (19–30) and 3 (2–4) at 1 and 17 months after dose 3 and 259 (184–363) 1 month after dose 4. Dose 4 had no safety concerns. Conclusions Immune response to MeNZB was most sustained in adults. In infants, bactericidal titres decayed almost to baseline by 7 months after dose 3. Toddlers showed marked immune response following a fourth dose suggesting memory. Persisting antibody is likely to be necessary for ongoing protection, as seen with serogroup C meningococci.Keywords
This publication has 33 references indexed in Scilit:
- Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd ImmunityClinical and Vaccine Immunology, 2010
- Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C VaccineClinical and Vaccine Immunology, 2010
- Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal diseaseVaccine, 2009
- Immunogenicity, Reactogenicity, and Safety of a P1.7b,4 Strain-Specific Serogroup B Meningococcal Vaccine Given to PreteensClinical and Vaccine Immunology, 2007
- Immunogenicity and Safety of a Combination of Two Serogroup B Meningococcal Outer Membrane Vesicle VaccinesClinical and Vaccine Immunology, 2007
- Comparison and Correlation of Neisseria meningitidis Serogroup B Immunologic Assay Results and Human Antibody Responses following Three Doses of the Norwegian Meningococcal Outer Membrane Vesicle Vaccine MenBvacInfection and Immunity, 2006
- Persisting Immune Responses Indicating Long-Term Protection after Booster Dose with Meningococcal Group B Outer Membrane Vesicle VaccineClinical and Vaccine Immunology, 2006
- Understanding the Immune Responses to the Meningococcal Strain-Specific Vaccine MeNZB Measured in Studies of InfantsClinical and Vaccine Immunology, 2006
- Interlaboratory Standardization of the Measurement of Serum Bactericidal Activity by Using Human Complement against Meningococcal Serogroup B, Strain 44/76-SL, before and after Vaccination with the Norwegian MenBvac Outer Membrane Vesicle VaccineClinical and Vaccine Immunology, 2005
- Approximate Is Better than "Exact" for Interval Estimation of Binomial ProportionsThe American Statistician, 1998